efaroxan has been researched along with atrial natriuretic factor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gutkowska, J; Mukaddam-Daher, S | 1 |
| Cao, C; Kang, CW; Kim, SH; Kim, SZ | 1 |
2 other study(ies) available for efaroxan and atrial natriuretic factor
| Article | Year |
|---|---|
Atrial natriuretic peptide is involved in renal actions of moxonidine.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Benzofurans; Cyclic GMP; Diuresis; Dose-Response Relationship, Drug; Female; Imidazoles; Imidazoline Receptors; Injections, Intravenous; Kidney; Natriuresis; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Drug; Yohimbine | 2000 |
Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Atrial Function; Atrial Natriuretic Factor; Benzofurans; Blood Pressure; Cardiomegaly; Clonidine; Heart Atria; Hemodynamics; Imidazoles; Imidazoline Receptors; Male; Rats; Rats, Sprague-Dawley; Receptors, Drug; Yohimbine | 2004 |